奥氮平联合格拉司琼控制乳腺癌化疗所致恶心呕吐的疗效观察

The observation of the effects of olanzapine combined with granisetron in preventing nausea and vomiting induced by chemotherapy of breast cancer

目的观察并比较奥氮平联合格拉司琼与单用格拉司琼控制乳腺癌化疗所致恶心呕吐的疗效。方法 120例乳腺癌患者被随机分为研究组(60例)及对照组(60例),研究组和对照组均在化疗前30 min静脉滴注格拉司琼3 mg,研究组自化疗第1天早晨开始口服奥氮平10 mg,连用3天,第1个周期化疗结束后评价止吐效果。结果研究组的急性恶心呕吐的发生率(33.3%)和迟发性恶心呕吐的发生率(18.3%)均明显低于对照组(53.3%和40%),差异有统计学意义(P<0.05)。结论与单用格拉司琼相比,奥氮平联合格拉司琼对于控制乳腺癌化疗所致急性恶心呕吐和延迟性恶心呕吐的效果更好。

Objective To observe the effects of combined therapy of olanzapine and granisetron vs granisetron monotherapy in preventing nausea and vomiting induced by chemotherapy of breast cancer. Method 120 cases of breast cancer were randomized into study group（60 cases） or control group（60 cases）, and both groups received granisetron 3 mg, i.v. about 30 min before chemotherapy. Olanzapine（10 mg/kg per day） was administered in the morning from the first day of chemotherapy for three days in the study group, and the antiemetic effect of the first cycle of chemotherapy was evaluated. Result The incidences of acute and delayed nausea and vomiting in study group were all significantly lower than that in control group as 33.3% vs 53.3%（P〈 0.05）, and 18.3% vs 40%（P〈 0.01）. Conclusion Compared with granisetron monotherapy, olanzapine combined with granisetron is much more efficient in preventing acute and delayed nausea and vomiting induced by chemotherapy of breast cancer.